In exclusive clinical partnership with KPCIRC
OnKommon
Get Started
  1. Home
  2. Signature

Pillar 2 · the tests that feed a decision

Signature

Molecular tests for solid tumours and blood cancers. Each reads the DNA of the cancer and feeds the result into Blueprint Care, where it becomes a signed decision.

01The molecular tests

The test that feeds the decision

Signature reads the DNA of the cancer, from a blood draw, a bone marrow sample or a tissue block, and feeds the result into Blueprint Care where it becomes a ranked, signed decision.

Signature is the test. Blueprint Care is the decision.

6tests across both families
523genes on the widest panel
35PGx genes in every solid-tumour tier
2assay families: solid and blood

02Solid tumour and blood cancer

Every Signature test

Two assay families, because solid tumours and leukaemias are driven by different biology and need different panels.

Solid tumour

Blood cancer

Every result feeds Blueprint Care

03By the question you need answered

Choosing a solid-tumour tier

Stage 01

Fastest

Signature STb

33 actionable genes and 13 fusion genes from blood. For urgent decisions.

See STb

Stage 02

Baseline

Signature STb O

118 genes from blood. Broad, and the baseline Sentinel monitoring needs.

See STb O

Stage 03

Fullest

Signature STb O+

523 genes plus copy number, fusions and signatures. The complete liquid-biopsy picture.

See STb O+

Stage 04

Tissue

Signature STt O

Comprehensive profiling direct from an FFPE tumour block.

See STt O
Diagram placeholder

Panel breadth compared, at a glance

What goes here: Horizontal bar comparison of the four solid-tumour tiers showing gene count and what each adds: drivers, fusions, copy number, signatures, immune, PGx. Make the jump from 33 to 118 to 523 visually obvious. Mark which tiers can serve as a Sentinel baseline. Stack the bars at mobile width so it stays readable.

04No confusing add-ons

What every tier includes

The markers your doctor needs are built into every tier, not sold separately.

Driver mutations

SNVs and InDels across the tier’s gene set.

Gene fusions

Rearrangements for the relevant targets.

Immune profile

TMB, MSI and MMR reported on every tier.

Pharmacogenomics

The 35-gene drug-response panel.

Copy number and signatures

From the 118-gene tier upward.

Tumour fraction

How much tumour DNA was present, so results are read in context.

0535 genes, every tier

The pharmacogenomics panel

Beyond what drives the cancer, we read how you are likely to handle the drugs used to treat it. This can prevent severe reactions and guide safe dosing before the first dose.

35 genes, on every tier

Drug metabolism and response

25 genes

How you process and react to common cancer drugs.

  • DPYD
  • UGT1A1
  • TPMT
  • NUDT15
  • CYP2D6
  • CYP2C19
  • CYP3A5
  • CYP2B6
  • CYP2C9
  • VKORC1
  • ABCB1
  • ABCG2
  • SLCO1B1
  • SLC22A1
  • SLC22A2
  • CYP3A4
  • CYP1A2
  • GSTP1
  • GSTA1
  • GSTM1
  • GSTT1
  • TYMS
  • MTHFR
  • ENOSF1
  • CES2

Drug hypersensitivity (HLA)

4 genes

Flags risk of severe, sometimes fatal, skin or hypersensitivity reactions.

  • HLA-B*57:01
  • HLA-B*58:01
  • HLA-B*15:02
  • HLA-A*31:01

Antibody response

2 genes

Influences how well certain therapeutic antibodies engage the immune system.

  • FCGR2A
  • FCGR3A

DNA repair and platinum response

4 genes

Relates to how a tumour responds to platinum chemotherapy.

  • ERCC1
  • ERCC5
  • XRCC1
  • XRCC3

Pharmacogenomics is a safety net, and safety nets should never be optional.

DPYD

Predicts severe toxicity from fluoropyrimidines such as 5-FU and capecitabine.

UGT1A1

Guides safe dosing of irinotecan.

TPMT and NUDT15

Predict toxicity from thiopurines, important in leukaemia regimens.

06

Blood or tissue?

  1. Question 1Do you have a usable tumour block?

    If a recent FFPE block exists and tissue is preferred, choose STt O.

  2. Question 2Is surgery difficult, or is timing urgent?

    A blood draw avoids a surgical biopsy and can be faster.

  3. Question 3How much breadth do you need?

    Fast and actionable: STb. Broad plus monitoring: STb O. The fullest picture: STb O+.

07

What a Signature test cannot do

A negative result means the tested genes carried no reportable changes. It does not mean cancer is absent, and it does not rule out alterations outside the panel.

Liquid biopsies depend on tumour DNA shedding. Occasionally, changes seen in blood come from normal ageing blood cells rather than the tumour. Every report states these limits plainly, and a clinician reads the result alongside your full clinical picture.

Research and evidence

The science behind this

Liquid-biopsy and tissue comprehensive profiling are validated in large studies and recommended by international guidelines.

Study 1

Blood-based profiling, extensively validated

A cfDNA comprehensive genomic profiling assay was validated across more than 7,500 tests and over 30,000 variants, spanning 300+ genes and 30+ cancer types.

Woodhouse R, et al. PLoS ONE, 2020.

Study 2

Guidelines support ctDNA profiling

NCCN and ESMO recommend ctDNA profiling as an alternative or complement to tissue. ASCO recommends blood cfDNA as the specimen of choice for comprehensive profiling in advanced breast cancer.

Review, Cancers, 2022.

Study 3

Plasma genotyping finds more targets

Adding plasma ctDNA testing to tissue in advanced lung cancer increased detection of targetable alterations and the number of patients who received matched therapy.

Aggarwal C, et al. JAMA Oncology, 2019.

These independent, peer-reviewed studies describe the class of technology we use. They are shared for education. They are not results for any individual and not a promise of benefit.

Being clear about our limits

What we do and do not do

What we DO

  • Read the tumour’s drivers, fusions, immune and PGx profile
  • Feed a ranked, tumour-board-signed Blueprint Care decision
  • Report tumour fraction and per-gene coverage openly
  • Work from blood or tissue, and repeat over time when needed

What we DON’T do

  • Diagnose cancer or decide treatment on their own
  • Rule out cancer from a “not detected” result
  • Detect changes in genes outside the panel
  • Guarantee a drug, its approval, cover, or that it will work
Plain-language glossary (9 terms)
TermWhat it means
ctDNACirculating tumour DNA, tumour fragments in blood that a liquid biopsy reads.
SNV / InDelA single-letter DNA change, or a small insertion or deletion.
FusionTwo genes joined abnormally, creating a driver that is often highly treatable.
CNVCopy-number variation, extra or missing copies of a gene.
TMBTumour mutational burden, how many mutations a tumour carries.
MSI / MMRSignals of faulty DNA repair that often predict immunotherapy response.
PGxPharmacogenomics, how your genes affect the way you handle specific drugs.
Tumour fractionHow much of the blood DNA came from the tumour.
CCRComplete coding region, meaning the whole gene is read rather than known hotspots.

Take the next step

Three ways forward. Pick the one that fits today.

01

Book a free consultation

A no-obligation conversation with our care team, arranged through KPCIRC.

Book a consultation
02

Begin Blueprint Care

Commission your decision report and a dedicated clinical team.

Explore Blueprint Care
03

Ask on WhatsApp, free

Signal replies to your first question within four hours, at no cost.

Start with Signal